2022 Oct 21-24
AACR Special Conference (poster B63)
Exploratory immune phenotyping of longitudinal blood samples from the first-in-human phase 1 clinical trial of a novel autologous cellular therapy in patients with metastatic solid tumors
Results and Conclusions
- Circulating cytokine levels showed modulation of systemic cytokine levels in all 3 patients after SUPLEXA treatments
- SUPLEXA cells showed highly similar phenotypes between all 3 patients showing induction of the predicted SUPLEXA cell populations –NK and NKT cells, CD8 and CD4 T cells, TCRγδT cells, with no B cells or myeloid cells.
- T cells, NK cells, and NKT cells in SUPLEXA showed high expression of the cytotoxic effector enzymes, granzyme B and perforin.
- Preliminary analysis of longitudinal PBMCs by CyTOF suggest that several specific subpopulations of myeloid cells, NK cells, CD4 T cells, and B cells were affected by SUPLEXA treatment suggesting a change in immune health